The National Synchrotron Light Source (NSLS) and its future successor, NSLS-II, can help companies large and small solve research and manufacturing problems, generate new technologies and products, and stay competitive. The Photon Sciences Directorate would like to encourage greater use of its facilities by industrial researchers and facilitate collaborations between industry and NSLS staff, as well as government and academic institutions.
The results of a clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International Inc. revealed promising results. The vaccine produced substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States.
The next big frontier for battery technology is efficient, grid-scale storage. Experiments to exploit the properties of single-use alkaline batteries for large-scale batteries could lead to the next energy revolution and provide safe storage for immense amounts of power.
In a study conducted in part at NSLS, a research group has gained valuable information about a material being investigated for use in an emerging technology for renewable energy production: using sunlight-absorbing semiconductors to split water molecules and yield hydrogen gas, which can be fed into a fuel cell to generate electricity or used as fuel itself.
Detailed studies of one of the best-performing organic photovoltaic materials reveal an unusual bilayer lamellar structure that may help explain the material’s superior performance at converting sunlight to electricity and guide the synthesis of new materials with even better properties.
An international research team has succeeded in manufacturing the world’s first flexible organic transistor that is robust enough to withstand the high temperature medical sterilization process, making it a step toward the development of implantable electronic medical devices.
Scientists at BNL and Stony Brook University have discovered a key difference in the way human cells and Mycobacterium tuberculosis bacteria, which cause TB, deliver unwanted proteins — marked with a “kiss of death” sequence — to their respective cellular recycling factories.
U.S. Department of Energy’s Brookhaven National Laboratory and Stony Brook University’s Institute of Chemical Biology and Drug Discovery (ICB&DD) scientists were selected to receive up to $1.4 million in research funds from the Department of Defense to develop anti-botulism drugs.